Qualigen Therapeutics Faces Delisting Concerns
Ticker: AIXC · Form: 8-K · Filed: May 30, 2024 · CIK: 1460702
| Field | Detail |
|---|---|
| Company | Qualigen Therapeutics, INC. (AIXC) |
| Form Type | 8-K |
| Filed Date | May 30, 2024 |
| Risk Level | high |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $1.00, $2,500,000 m |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
TL;DR
Qualigen Therapeutics might get delisted, stock trading could be in trouble.
AI Summary
Qualigen Therapeutics, Inc. filed an 8-K on May 30, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The company's principal executive offices are located at 5857 Owens Avenue, Suite 300, Carlsbad, California. The filing date for this report is May 30, 2024, with the earliest event reported on May 23, 2024.
Why It Matters
This filing indicates potential delisting from a stock exchange, which could significantly impact the liquidity and trading of Qualigen Therapeutics' stock.
Risk Assessment
Risk Level: high — A notice of delisting directly threatens the company's ability to remain publicly traded, posing a significant risk to investors.
Key Players & Entities
- Qualigen Therapeutics, Inc. (company) — Registrant
- May 23, 2024 (date) — Earliest event reported
- May 30, 2024 (date) — Filing date
- 5857 Owens Avenue, Suite 300, Carlsbad, California (location) — Principal executive offices
FAQ
What specific listing rule or standard has Qualigen Therapeutics failed to satisfy?
The filing does not specify the exact rule or standard that Qualigen Therapeutics has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on May 23, 2024.
Where are Qualigen Therapeutics' principal executive offices located?
Qualigen Therapeutics' principal executive offices are located at 5857 Owens Avenue, Suite 300, Carlsbad, California.
What is the Commission File Number for Qualigen Therapeutics?
The Commission File Number for Qualigen Therapeutics is 001-37428.
What is the SIC code for Qualigen Therapeutics?
The Standard Industrial Classification (SIC) code for Qualigen Therapeutics is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,347 words · 5 min read · ~4 pages · Grade level 13.8 · Accepted 2024-05-30 16:00:18
Key Financial Figures
- $1.00 — ice for its common stock has been below $1.00 per share for 30 consecutive business d
- $2,500,000 m — Company that it did not comply with the $2,500,000 minimum stockholders' equity requirement,
Filing Documents
- form8-k.htm (8-K) — 48KB
- ex99-1.htm (EX-99.1) — 15KB
- ex99-1_001.jpg (GRAPHIC) — 22KB
- 0001493152-24-021962.txt ( ) — 269KB
- qlgn-20240523.xsd (EX-101.SCH) — 3KB
- qlgn-20240523_lab.xml (EX-101.LAB) — 33KB
- qlgn-20240523_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. QUALIGEN THERAPEUTICS, INC. Date: May 30, 2024 By: /s/ Michael S. Poirier Michael S. Poirier, Chief Executive Officer